Cogent Biosciences, Inc. COGT
32.31
0.88
2.80%
as of 25 Sep
- Market cap
- $5.5B
- P/E
- 0.0×
Follow COGT
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | — |
+8 more quarters Free account |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
13.36 | 14.94 | 14.08 | 6.28 | |
Current Ratio |
13.57 | 15.14 | 14.23 | 6.38 | |
Net Debt/EBITDA |
5.55 | 6.19 | 6.80 | 4.20 | |
Debt/Assets |
26.78% | 24.71% | 23.77% | 10.39% | |
Debt/Equity |
0.42 | 0.37 | 0.35 | 0.15 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.80 | 0.89 | 0.77 | 0.79 | |
Capex/Depreciation |
(5.78) | 1.63 | 4.27 | (0.08) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.45) | (0.54) | (0.61) | (0.47) | |
Capex per Share |
0.00 | 0.00 | (0.01) | 0.00 | |
Free Cash Flow per Share |
(0.45) | (0.54) | (0.62) | (0.47) | |
Cash per Share |
4.63 | 5.34 | 6.99 | 2.84 | |
Shareholders Equity per Share |
3.11 | 3.75 | 4.94 | 2.20 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.11 | 3.75 | 4.94 | 2.20 | |
Free Cash Flow |
(77.64) | (87.33) | (79.92) | (64.35) | |
Working Capital |
745.52 | 819.82 | 846.40 | 335.00 | |
Capital Expenditures |
(0.37) | (0.45) | (0.81) | (0.06) | |
Net Current Asset Value |
502.66 | 582.49 | 609.12 | 273.78 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% | |
| Other line items | |||||
Average Payables |
12.06 | 13.95 | 10.76 | 15.55 | |
Average Assets |
554.68 | 593.40 | 632.75 | 404.97 | |
Average Common Equity |
257.38 | 326.89 | 346.33 | 199.30 |
Columns are period end dates